Sang Min Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sang Min Park has a total of 139 co-authors. Here are the top co-authors by number of shared publications:
- Mi-Hyang Jung
Division of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
10 shared publications - Jong-Chan Youn
Division of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, Catholic Research Institute for Intractable Cardiovascular Disease, College of Medicine, The Catholic University of Korea, Seoul, Korea
9 shared publications - Seong-Mi Park
Division of Cardiology, Korea University Anam Hospital, Seoul, Republic of Korea
9 shared publications - Byung-Su Yoo
Division of Cardiology, Department of Internal Medicine, Yonsei University, Wonju College of Medicine, Wonju, Korea
8 shared publications - Darae Kim
Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
8 shared publications - Dong-Hyuk Cho
Division of Cardiology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea
8 shared publications
Latest Publications
- Open Access
- 3 March 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (5) , e043441
Biodegradable Polymer Versus Polymer‐Free Ultrathin Sirolimus‐Eluting Stents in Complex Percutaneous Coronary Intervention: Post Hoc Analysis of the Stent Arm Registry From the HOST‐IDEA Randomized Trial
Background: The performance of third‐generation drug‐eluting stents with ultrathin struts and advanced polymer technology in complex percutaneous coronary intervention (PCI) remains unclear. This study compared the clinical outcomes of Coroflex ISAR polymer‐free sirolimus‐eluting stent (SES) and Orsiro biodegradable polymer SES, 2 third‐generation drug‐eluting stents, based on PCI complexity. Methods: A post hoc analysis of the HOST‐IDEA (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis–Coronary Intervention With Next‐Generation Drug‐Eluting Stent Platforms and Abbreviated Dual Antiplatelet Therapy) trial, which randomized 2013 patients undergoing PCI with Coroflex ISAR or Orsiro SES based on the duration of dual antiplatelet therapy (3 versus 12 months), was conducted herein. The baseline characteristics were balanced through propensity score matching. Complex PCI satisfied ≥1 of the following criteria: ≥3 stents implanted, ≥3 lesions or vessels treated, bifurcation PCI, total stent length of ≥60 mm, left main PCI, or heavy calcification. Target lesion failure (TLF) at 1 year, a composite of cardiac death, target vessel myocardial infarction, and clinically driven target lesion revascularization, was the primary end point. Results: Each stent group comprised 546 patients after propensity score matching. In total, 336 and 756 patients underwent complex PCI and noncomplex PCI, respectively. Complex PCI exhibited a significant association with a higher risk of TLF compared with noncomplex PCI (5.7% versus 1.3%, P P =0.02). However, the TLF rates in the 2 stent groups in the noncomplex PCI group were comparable (1.1% versus 1.6%; HR, 0.66 [95% CI, 0.19–2.35]; P =0.53; P for interaction=0.04). Multivariable analysis identified Coroflex ISAR SES and chronic kidney disease as independent predictors of TLF. Conclusions: Orsiro SES was associated with significantly better TLF outcomes than the Coroflex ISAR SES in complex PCI; however, no significant difference was observed in noncomplex PCI.
- 3 March 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (5) , e043441
Open AccessBiodegradable Polymer Versus Polymer‐Free Ultrathin Sirolimus‐Eluting Stents in Complex Percutaneous Coronary Intervention: Post Hoc Analysis of the Stent Arm Registry From the HOST‐IDEA Randomized Trial
Background: The performance of third‐generation drug‐eluting stents with ultrathin struts and advanced polymer technology in complex percutaneous coronary intervention (PCI) remains unclear. This study compared the clinical outcomes of Coroflex ISAR polymer‐free sirolimus‐eluting stent (SES) and Orsiro biodegradable polymer SES, 2 third‐generation drug‐eluting stents, based on PCI complexity. Methods: A post hoc analysis of the HOST‐IDEA (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis–Coronary Intervention With Next‐Generation Drug‐Eluting Stent Platforms and Abbreviated Dual Antiplatelet Therapy) trial, which randomized 2013 patients undergoing PCI with Coroflex ISAR or Orsiro SES based on the duration of dual antiplatelet therapy (3 versus 12 months), was conducted herein. The baseline characteristics were balanced through propensity score matching. Complex PCI satisfied ≥1 of the following criteria: ≥3 stents implanted, ≥3 lesions or vessels treated, bifurcation PCI, total stent length of ≥60 mm, left main PCI, or heavy calcification. Target lesion failure (TLF) at 1 year, a composite of cardiac death, target vessel myocardial infarction, and clinically driven target lesion revascularization, was the primary end point. Results: Each stent group comprised 546 patients after propensity score matching. In total, 336 and 756 patients underwent complex PCI and noncomplex PCI, respectively. Complex PCI exhibited a significant association with a higher risk of TLF compared with noncomplex PCI (5.7% versus 1.3%, P P =0.02). However, the TLF rates in the 2 stent groups in the noncomplex PCI group were comparable (1.1% versus 1.6%; HR, 0.66 [95% CI, 0.19–2.35]; P =0.53; P for interaction=0.04). Multivariable analysis identified Coroflex ISAR SES and chronic kidney disease as independent predictors of TLF. Conclusions: Orsiro SES was associated with significantly better TLF outcomes than the Coroflex ISAR SES in complex PCI; however, no significant difference was observed in noncomplex PCI.
- Open Access
- 1 January 2026
- Published by XMLink in CardioMetabolic Syndrome Journal
- Vol. 6 (2) , 193
Cardiometabolic Syndrome Part 2: Pharmacological Management, Public Health Strategies, and Future Direction
Lim S, et al. Cardiometab Syndr J. 2026 ;6:e26. https://doi.org/10.51789/cmsj.2026.6.e26
- 1 January 2026
- Published by XMLink in CardioMetabolic Syndrome Journal
- Vol. 6 (2) , 193
Open AccessCardiometabolic Syndrome Part 2: Pharmacological Management, Public Health Strategies, and Future Direction
Lim S, et al. Cardiometab Syndr J. 2026 ;6:e26. https://doi.org/10.51789/cmsj.2026.6.e26
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Lipid and Atherosclerosis
- Vol. 15 (1) , 2-25
A Position Paper on Lipoprotein(a) From the Lipoprotein(a) Task Force of the Korean Society of Lipid and Atherosclerosis: Current Evidence, Clinical Applications, and Future Directions
Lipoprotein(a) [Lp(a)] is a genetically determined risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve stenosis (CAVS), with plasma levels largely unaffected by lifestyle modification or conventional lipid-lowering therapy. Although international guidelines increasingly recognize Lp(a) as a risk-enhancing factor, in many Asian populations thresholds for high Lp(a) and treatment strategies remain undefined. This Korean position paper, developed by the Lp(a) Task Force of the Korean Society of Lipid and Atherosclerosis, presents an evidence-based summary of the pathophysiology, clinical relevance, and therapeutic landscape surrounding Lp(a), with a focus on Korean-specific data. It reviews the genetic architecture of Lp(a), ethnic variability in concentrations, and its mechanistic roles in inflammation, thrombosis, and calcification. Based on large Korean cohorts, a 3-tiered classification is proposed of normal (<30 mg/dL), borderline high (30–49 mg/dL), and high (≥50 mg/dL), harmonizing global thresholds with local data. The document also highlights the limitations of current Lp(a) assays in Korea, and calls for standardized, isoform-insensitive testing. Novel therapeutics, including antisense oligonucleotides, small interfering RNAs, and small molecular inhibitors, have shown promising Lp(a)-lowering effects, with multiple phase 3 trials currently ongoing, or in planning. Given the unmet clinical need, the paper recommends incorporating Lp(a) into cardiovascular risk assessment, and calls for Korean-specific longitudinal studies, national screening strategies, and participation in clinical trials. These efforts will help clarify Lp(a)-associated risk in Korean patients and guide the adoption of future targeted therapies.
- 1 January 2026
- Published by XMLink in Journal of Lipid and Atherosclerosis
- Vol. 15 (1) , 2-25
Open AccessA Position Paper on Lipoprotein(a) From the Lipoprotein(a) Task Force of the Korean Society of Lipid and Atherosclerosis: Current Evidence, Clinical Applications, and Future Directions
Lipoprotein(a) [Lp(a)] is a genetically determined risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve stenosis (CAVS), with plasma levels largely unaffected by lifestyle modification or conventional lipid-lowering therapy. Although international guidelines increasingly recognize Lp(a) as a risk-enhancing factor, in many Asian populations thresholds for high Lp(a) and treatment strategies remain undefined. This Korean position paper, developed by the Lp(a) Task Force of the Korean Society of Lipid and Atherosclerosis, presents an evidence-based summary of the pathophysiology, clinical relevance, and therapeutic landscape surrounding Lp(a), with a focus on Korean-specific data. It reviews the genetic architecture of Lp(a), ethnic variability in concentrations, and its mechanistic roles in inflammation, thrombosis, and calcification. Based on large Korean cohorts, a 3-tiered classification is proposed of normal (<30 mg/dL), borderline high (30–49 mg/dL), and high (≥50 mg/dL), harmonizing global thresholds with local data. The document also highlights the limitations of current Lp(a) assays in Korea, and calls for standardized, isoform-insensitive testing. Novel therapeutics, including antisense oligonucleotides, small interfering RNAs, and small molecular inhibitors, have shown promising Lp(a)-lowering effects, with multiple phase 3 trials currently ongoing, or in planning. Given the unmet clinical need, the paper recommends incorporating Lp(a) into cardiovascular risk assessment, and calls for Korean-specific longitudinal studies, national screening strategies, and participation in clinical trials. These efforts will help clarify Lp(a)-associated risk in Korean patients and guide the adoption of future targeted therapies.
- Open Access
- 1 January 2026
- Published by XMLink in Korean Circulation Journal
- Vol. 56 (1) , 9-32
A Position Paper on Lipoprotein(a) From the Lipoprotein(a) Task Force of the Korean Society of Lipid and Atherosclerosis: Current Evidence, Clinical Applications, and Future Directions
Jang Y, et al. Korean Circ J. 2025 Dec;56:e52. https://doi.org/10.4070/kcj.2025.0388
- 1 January 2026
- Published by XMLink in Korean Circulation Journal
- Vol. 56 (1) , 9-32
Open AccessA Position Paper on Lipoprotein(a) From the Lipoprotein(a) Task Force of the Korean Society of Lipid and Atherosclerosis: Current Evidence, Clinical Applications, and Future Directions
Jang Y, et al. Korean Circ J. 2025 Dec;56:e52. https://doi.org/10.4070/kcj.2025.0388
- Open Access
- 1 January 2025
- Published by XMLink in CardioMetabolic Syndrome Journal
- Vol. 5 (2) , 124
Urinary Cotinine Testing Elevates the Standard for Measuring Smoking Exposure in Patients With Cardiometabolic Risk
Park SM. Cardiometab Syndr J. 2025 Aug;5:e15. https://doi.org/10.51789/cmsj.2025.5.e15
- 1 January 2025
- Published by XMLink in CardioMetabolic Syndrome Journal
- Vol. 5 (2) , 124
Open AccessUrinary Cotinine Testing Elevates the Standard for Measuring Smoking Exposure in Patients With Cardiometabolic Risk
Park SM. Cardiometab Syndr J. 2025 Aug;5:e15. https://doi.org/10.51789/cmsj.2025.5.e15
- Open Access
- 1 January 2025
- Published by XMLink in Journal of Cardiovascular Intervention
- Vol. 4 (4) , 268
Trends and In-Hospital Outcomes of Percutaneous Coronary Intervention in Korea: Insights From the 2014, 2016, and 2018 K-PCI Registry Cohorts
Ahn SG, et al. J Cardiovasc Interv. 2025 May;4:e21. https://doi.org/10.54912/jci.2025.0011
- 1 January 2025
- Published by XMLink in Journal of Cardiovascular Intervention
- Vol. 4 (4) , 268
Open AccessTrends and In-Hospital Outcomes of Percutaneous Coronary Intervention in Korea: Insights From the 2014, 2016, and 2018 K-PCI Registry Cohorts
Ahn SG, et al. J Cardiovasc Interv. 2025 May;4:e21. https://doi.org/10.54912/jci.2025.0011
- Open Access
- 1 January 2024
- Published by XMLink in Yonsei Medical Journal
- Vol. 65 (12) , 777-780
Percutaneous Coronary Intervention and Long-Term Management of Acute Myocardial Infarction in a Hemophilia Patient: Overcoming Bleeding Challenges
Park SM, et al. Yonsei Med J. 2024 Aug;65:e59. https://doi.org/10.3349/ymj.2023.0577
- 1 January 2024
- Published by XMLink in Yonsei Medical Journal
- Vol. 65 (12) , 777-780
Open AccessPercutaneous Coronary Intervention and Long-Term Management of Acute Myocardial Infarction in a Hemophilia Patient: Overcoming Bleeding Challenges
Park SM, et al. Yonsei Med J. 2024 Aug;65:e59. https://doi.org/10.3349/ymj.2023.0577
- Open Access
- 1 January 2024
- Published by XMLink in Korean Circulation Journal
- Vol. 54 (8) , 499-512
Serial Vascular Responses of Balloon-Expandable Stent With Biodegradable Film-Type Graft in a Rabbit Iliac Artery Dissection Model (BioGard Study)
Park SM, et al. Korean Circ J. 2024 Jun;54:e63. https://doi.org/10.4070/kcj.2024.0049
- 1 January 2024
- Published by XMLink in Korean Circulation Journal
- Vol. 54 (8) , 499-512
Open AccessSerial Vascular Responses of Balloon-Expandable Stent With Biodegradable Film-Type Graft in a Rabbit Iliac Artery Dissection Model (BioGard Study)
Park SM, et al. Korean Circ J. 2024 Jun;54:e63. https://doi.org/10.4070/kcj.2024.0049
- Open Access
- 1 January 2023
- Published by XMLink in Clinical Hypertension
- Vol. 29 (1) , 1-12
Standardized protocol of blood pressure measurement and quality control program for the Korea National Health and Nutrition Examination Survey
Accurate blood pressure (BP) measurement is crucial for hypertension detection and management. The Korea National Health and Nutrition Examination Survey (KNHANES) assesses the health of Koreans using representative cross-sectional data. BP measurements were historically done with mercury sphygmomanometers for participants aged ≥10 years. However, KNHANES transitioned to Greenlight 300TM (mercury-free auscultatory device) in 2020 for participants aged ≥6 years and used dual devices (Microlife WatchBP Office AFIB and Greenlight) in 2021-2022. To ensure consistency, KNHANES will adopt Microlife as the unified BP device with Greenlight for device validation from 2023. Under the new protocol, participants aged ≥6 years will have their BP measured three times at 30-second intervals after a 5-minute rest under ambient temperature (20-25℃) and noise ≤65 dB. The average of the 2nd and 3rd readings will be used as the representative BP value. The quality control (QC) program involves four trained examiners passing the “quality control and assurance of BP measurement program” three times annually, and undergoing “video monitoring of weekly calibration process” once a year. Additionally, the QC team will conduct “on-site evaluations of BP measurement” at mobile examination centers three times a year. A Five-Step QC process for BP devices was also developed. This document outlines the standardized BP measurement protocol and rigorous QC program in KNHANES, aiming to ensure accurate and reliable BP data for epidemiological research and public health policymaking in South Korea.
- 1 January 2023
- Published by XMLink in Clinical Hypertension
- Vol. 29 (1) , 1-12
Open AccessStandardized protocol of blood pressure measurement and quality control program for the Korea National Health and Nutrition Examination Survey
Accurate blood pressure (BP) measurement is crucial for hypertension detection and management. The Korea National Health and Nutrition Examination Survey (KNHANES) assesses the health of Koreans using representative cross-sectional data. BP measurements were historically done with mercury sphygmomanometers for participants aged ≥10 years. However, KNHANES transitioned to Greenlight 300TM (mercury-free auscultatory device) in 2020 for participants aged ≥6 years and used dual devices (Microlife WatchBP Office AFIB and Greenlight) in 2021-2022. To ensure consistency, KNHANES will adopt Microlife as the unified BP device with Greenlight for device validation from 2023. Under the new protocol, participants aged ≥6 years will have their BP measured three times at 30-second intervals after a 5-minute rest under ambient temperature (20-25℃) and noise ≤65 dB. The average of the 2nd and 3rd readings will be used as the representative BP value. The quality control (QC) program involves four trained examiners passing the “quality control and assurance of BP measurement program” three times annually, and undergoing “video monitoring of weekly calibration process” once a year. Additionally, the QC team will conduct “on-site evaluations of BP measurement” at mobile examination centers three times a year. A Five-Step QC process for BP devices was also developed. This document outlines the standardized BP measurement protocol and rigorous QC program in KNHANES, aiming to ensure accurate and reliable BP data for epidemiological research and public health policymaking in South Korea.
- Open Access
- 1 January 2023
- Published by XMLink in International Journal of Heart Failure
- Vol. 5 (3) , 111-126
Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Advanced and Acute Heart Failure
Hyun J, et al. Int J Heart Fail. 2023 Jul;5:e16. https://doi.org/10.36628/ijhf.2023.0019
- 1 January 2023
- Published by XMLink in International Journal of Heart Failure
- Vol. 5 (3) , 111-126
Open AccessKorean Society of Heart Failure Guidelines for the Management of Heart Failure: Advanced and Acute Heart Failure
Hyun J, et al. Int J Heart Fail. 2023 Jul;5:e16. https://doi.org/10.36628/ijhf.2023.0019